Literature DB >> 590022

The effect of pentoxifylline on erythrocyte deformability and on phosphatide fatty acid distribution in the erythrocyte membrane.

R Schubotz, O Mühlfellner.   

Abstract

Ten maturity-onset diabetics with chronic vascular disease were treated with 400 mg pentoxifylline 3-times daily for 14 days. Erythrocyte deformability (using a filtration technique for whole blood) and phosphatide fatty acid distribution in the erythrocyte membrane were measured before and after the treatment period. Statistical analysis of the data showed that the erythrocyte filtration rate had increased significantly by the end of treatment (2alpha = 0.02), and that there were only slight changes in erythrocyte membrane phosphatide fatty acid levels. The drug was well tolerated, and there were no adverse laboratory findings in the parameters measured. On the basis of results described by other investigators, theimprovement in erythrocyte deformability was attributed to an increase in erythrocyte ATP levels. The authors discuss the importance of red cell fluidity for capillary perfusion.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 590022     DOI: 10.1185/03007997709115279

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  9 in total

Review 1.  Pharmacological approaches to the treatment of intermittent claudication.

Authors:  E G Bevan; P C Waller; L E Ramsay
Journal:  Drugs Aging       Date:  1992 Mar-Apr       Impact factor: 3.923

Review 2.  'Cerebroactive' drugs. Clinical pharmacology and therapeutic role in cerebrovascular disorders.

Authors:  A Spagnoli; G Tognoni
Journal:  Drugs       Date:  1983-07       Impact factor: 9.546

3.  Fat Grafts Augmented With Vitamin E Improve Volume Retention and Radiation-Induced Fibrosis.

Authors:  Darren B Abbas; Christopher V Lavin; Evan J Fahy; Michelle Griffin; Nicholas J Guardino; Rahim S Nazerali; Dung H Nguyen; Arash Momeni; Michael T Longaker; Derrick C Wan
Journal:  Aesthet Surg J       Date:  2022-08-01       Impact factor: 4.485

4.  Correction by pentoxifylline of the abnormal fluorescence polarization of erythrocyte membranes from diabetic patients.

Authors:  D Rahmani-Jourdheuil; I Juhan-Vague; C Roul; Y Mourayre; Z Mishal; J le Petit; P Vague
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 5.  Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy.

Authors:  A Ward; S P Clissold
Journal:  Drugs       Date:  1987-07       Impact factor: 9.546

6.  Therapeutic potentials of pentoxifylline for treatment of cardiovascular diseases.

Authors:  Ming Zhang; Yan-Jun Xu; Shushma A Mengi; Amarjit S Arneja; Naranjan S Dhalla
Journal:  Exp Clin Cardiol       Date:  2004

7.  The effect of denbufylline on the viscosity of rat whole blood and on the deformability (filterability) of rat blood cell suspensions.

Authors:  J J Jukna; C D Nicholson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-04       Impact factor: 3.000

8.  Treatment of homozygous sickle cell disease with pentoxifylline.

Authors:  A Sacerdote
Journal:  J Natl Med Assoc       Date:  1999-08       Impact factor: 1.798

9.  Effects of late administration of pentoxifylline and tocotrienols in an image-guided rat model of localized heart irradiation.

Authors:  Vijayalakshmi Sridharan; Preeti Tripathi; Sunil Sharma; Peter M Corry; Eduardo G Moros; Awantika Singh; Cesar M Compadre; Martin Hauer-Jensen; Marjan Boerma
Journal:  PLoS One       Date:  2013-07-22       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.